Patents by Inventor Michael A. Lerman
Michael A. Lerman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12285028Abstract: A mixing vessel for a frozen drink maker is described. The mixing vessel includes at least one curved sidewall defining a vessel chamber that is at least partly cylindrical configured to receive a drink product to be processed. The vessel chamber includes a front, a rear, a right side, a left side, a top, and a bottom, and the vessel chamber includes at least one asymmetric wall portion proximate to at least one of the front or the top of the vessel chamber. The at least one asymmetric wall portion is configured to promote slush flow within the vessel chamber.Type: GrantFiled: August 27, 2024Date of Patent: April 29, 2025Assignee: SharkNinja Operating LLCInventors: Michael Lerman, Macrae Benziger, Alexander Mularski, Vipul Mone
-
Patent number: 12279629Abstract: A mixing vessel for a frozen drink maker is described. The mixing vessel includes a curved sidewall defining a substantially cylindrical vessel chamber therein. The vessel chamber includes a front, a rear, a right side, a left side, and a top. The mixing vessel also includes at least one internal baffle configured to control slush flow within the vessel chamber. The at least one internal baffle may be a corner baffle positioned at the front top of the vessel chamber on either the right side or the left side, a side baffle extending laterally along the vessel chamber from the front to the rear, and/or a front baffle positioned at the front of the vessel chamber extending across the top from the right side to the left side.Type: GrantFiled: January 26, 2024Date of Patent: April 22, 2025Assignee: SharkNinja Operating LLCInventors: Michael Lerman, Macrae Benziger, Alexander Mularski, Vipul Mone
-
Publication number: 20230366707Abstract: A system for structural health monitoring of a panel includes a panel of a composite laminate structure. The system further includes a plurality of sensors disposed on at least a surface of the panel each configured to measure at least an electrical datum associated with a portion of the panel. The system further includes a data acquisition system electrically coupled to the plurality of sensors and configured to receive the at least an electrical datum. The system further includes an alert system electrically coupled to at least the data acquisition system and configured to alert a user based on the at least an electrical datum.Type: ApplicationFiled: May 12, 2023Publication date: November 16, 2023Inventors: Addis Tessema, John Perraut, McKevin Veloso, Paul Roehm, Jonathan M. Cabot, Michael Lerman, Scott Larson, Satya Immani
-
Publication number: 20220211281Abstract: A method, device, and system for evaluating a vessel of a patient, and in particular the hemodynamic impact of a stenosis within the vessel of a patient. Proximal and distal pressure measurements are made using first and second instrument while the first instrument is moved longitudinally through the vessel from a first position to a second position and the second instrument remains in a fixed longitudinal position within the vessel. A series of pressure ratio values are calculated, and a pressure ratio curve is generated. One or more stepped change in the pressure ratio curve are then identified and/or located using an Automatic Step Detection (ASD) process and/or algorithm.Type: ApplicationFiled: March 23, 2022Publication date: July 7, 2022Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: WENGUANG LI, QIAN LI, JUSTIN MICHAEL LERMAN, DAVID BURGESS
-
Patent number: 11311196Abstract: A method, device, and system for evaluating a vessel of a patient, and in particular the hemodynamic impact of a stenosis within the vessel of a patient. Proximal and distal pressure measurements are made using first and second instrument while the first instrument is moved longitudinally through the vessel from a first position to a second position and the second instrument remains in a fixed longitudinal position within the vessel. A series of pressure ratio values are calculated, and a pressure ratio curve is generated. One or more stepped change in the pressure ratio curve are then identified and/or located using an Automatic Step Detection (ASD) process and/or algorithm.Type: GrantFiled: February 22, 2019Date of Patent: April 26, 2022Assignee: Boston Scientific Scimed, Inc.Inventors: Wenguang Li, Qian Li, Justin Michael Lerman, David Burgess
-
Publication number: 20190261867Abstract: A method, device, and system for evaluating a vessel of a patient, and in particular the hemodynamic impact of a stenosis within the vessel of a patient. Proximal and distal pressure measurements are made using first and second instrument while the first instrument is moved longitudinally through the vessel from a first position to a second position and the second instrument remains in a fixed longitudinal position within the vessel. A series of pressure ratio values are calculated, and a pressure ratio curve is generated. One or more stepped change in the pressure ratio curve are then identified and/or located using an Automatic Step Detection (ASD) process and/or algorithm.Type: ApplicationFiled: February 22, 2019Publication date: August 29, 2019Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: WENGUANG LI, QIAN LI, JUSTIN MICHAEL LERMAN, DAVID BURGESS
-
Patent number: 9944951Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: GrantFiled: May 24, 2011Date of Patent: April 17, 2018Assignees: Board of Regents, The University of Texas System, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Patent number: 8386104Abstract: A system and method is provided for determining a mode of operation of a hybrid vehicle, obtaining torque data and speed data based on the mode of operation, and displaying component icons as well as a graphical representation of power flows. The graphical representation of power flows is displayed between pairs of the component icons. The component icons represent components of the hybrid vehicle including an engine, a battery, drive wheels, and an electric machine arrangement.Type: GrantFiled: March 22, 2010Date of Patent: February 26, 2013Assignee: Ford Global Technologies, LLCInventors: Ming Lang Kuang, Ryan Skaff, Paul Stephen Bryan, Michael Lerman
-
Publication number: 20120108880Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: ApplicationFiled: January 9, 2012Publication date: May 3, 2012Inventors: Lin Ji, John Minna, Jack Roth, Michael Lerman
-
Publication number: 20120076851Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: ApplicationFiled: May 24, 2011Publication date: March 29, 2012Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Patent number: 7977468Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: GrantFiled: October 31, 2007Date of Patent: July 12, 2011Assignees: Board of Regents of the University of Texas System, The United States of America as represented by the Department of Health and Human ServicesInventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Patent number: 7902441Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: GrantFiled: May 27, 2003Date of Patent: March 8, 2011Assignees: Board of Regents, The University of Texas, The United States of America as represented by the Department of Health and Human ServicesInventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Publication number: 20100305795Abstract: A system and method is provided for determining a mode of operation of a hybrid vehicle, obtaining torque data and speed data based on the mode of operation, and displaying component icons as well as a graphical representation of power flows. The graphical representation of power flows is displayed between pairs of the component icons. The component icons represent components of the hybrid vehicle including an engine, a battery, drive wheels, and an electric machine arrangement.Type: ApplicationFiled: March 22, 2010Publication date: December 2, 2010Applicant: FORD GLOBAL TECHNOLOGIES, LLCInventors: Ming Lang Kuang, Ryan Skaff, Paul Stephen Bryan, Michael Lerman
-
Patent number: 7781413Abstract: The present invention identifies the semaphorin polypeptide SEMA3B as a tumor suppressor. This molecule can inhibit tumor growth and induce apoptosis of tumor cells when produced internally in a cancer cell via gene transfer, or when applied extracellularly. These observations permit new methods for treatment and diagnosis of cancer.Type: GrantFiled: October 31, 2002Date of Patent: August 24, 2010Assignee: Board of Regents, The University of Texas SystemInventors: John Minna, Yoshio Tomizawa, Yoshitaka Sekido, Michael Lerman
-
Publication number: 20090023207Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: ApplicationFiled: October 31, 2007Publication date: January 22, 2009Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Publication number: 20040016006Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: ApplicationFiled: May 27, 2003Publication date: January 22, 2004Applicant: U.S. of America, represented by the Secretary, Department of Health and Human Services.Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Publication number: 20030166557Abstract: The present invention identifies the semaphorin polypeptide SEMA3B as a tumor suppressor. This molecule can inhibit tumor growth and induce apoptosis of tumor cells when produced internally in a cancer cell via gene transfer, or when applied extracellularly. These observations permit new methods for treatment and diagnosis of cancer.Type: ApplicationFiled: October 31, 2002Publication date: September 4, 2003Applicant: Board of Regents, The University of Texas SystemInventors: John Minna, Yoshio Tomizawa, Yoshitaka Sekido, Michael Lerman
-
Publication number: 20020164715Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: ApplicationFiled: July 10, 2001Publication date: November 7, 2002Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Patent number: 4912206Abstract: Four clones have been isolated from an adult human brain cDNA library using an oligonucleotide probe corresponding to the first 20 amino acids of the brain amyloid polypeptide of the Alzheimer's disease. The open reading frame of the sequenced clone coded for 97 amino acids including the known amino acid sequence of this polypeptide. The 3.5 kb messenger RNA has been detected in mammalian brains and human thymus. The gene is highly conserved in evolution and been mapped to human chromosome 21.Type: GrantFiled: February 26, 1987Date of Patent: March 27, 1990Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Dmitry Y. Goldgaber, Michael Lerman, D. Carleton Gajdusek
-
Patent number: 4145461Abstract: A water dispersion comprising i) up to about 50% by weight of a water-dispersible low molecular weight polyester having a number average molecular weight in the range of about 850-2500 and preferably 1100-1800 and an acid value in the range of about 40-85 milligrams of KOH/gram of said polyester (millig/g) and preferably in the range of about 45-65 millig/g, which comprises: (1) a non-linear polyester backbone having an acid value in the range of about 5-15 millig/g and preferably about 8-12 millig/g comprising the reaction product of an aliphatic polyol, an aromatic dicarboxylic acid, and a monocarboxylic acid and (2) pendant moieties of a polycarboxylic acid having at least one free carboxylic acid group and at least one ester linkage to said backbone, ii) about 0.5% to 4% by weight, as based upon said polyester, of a chelated titanate, and iii) a fugitive base, is disclosed to provide a useful warp sizing composition for synthetic yarn fibers.Type: GrantFiled: January 20, 1978Date of Patent: March 20, 1979Assignee: Standard Oil Company (Indiana)Inventors: Michael A. Lerman, John C. Lark